| 1 |
房延凤，马李杰，刘雁声，等. 非小细胞肺癌E19-Del、L858R突变临床特征分析[J/CD]. 中华肺部疾病杂志(电子版), 2020, 13(2): 164-168.
|
| 2 |
Jonna S, Subramaniam DS. Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update[J]. Discov Med, 2019, 27(148): 167-170.
|
| 3 |
张海涛，王 春，张映铭，等. 非小细胞肺癌患者EGFR突变率及与临床病理关系和TKI靶向治疗效果[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 175-180.
|
| 4 |
刘 姗，李兴德，宋沧桑，等. 铂类联合第三代化疗药物治疗非小细胞肺癌的药物基因组学研究进展[J]. 中国药房，2021, 32(3): 380-384.
|
| 5 |
林杰勋，徐象威，张鹏海，等. 非小细胞肺癌患者铂类药物化疗前后RMB5基因表达的变化及化疗预后分析[J]. 浙江医学，2021, 43(1): 56-59, 63.
|
| 6 |
Arrieta O, Barron F, Ramirez-Tirado LA, et al. Efficacy and safety of pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non-small cell lung cancer: the PROLUNG phase 2 Randomized Clinical Trial[J]. JAMA Oncol, 2020, 6(6): 856-864.
|
| 7 |
Yoshioka H, Shimokawa M, Seto T, et al. Final overall survival results of WJTOG3405, a randomized phase Ⅲ trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage ⅢB/Ⅳ or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer[J]. Ann Oncol, 2019, 30(12): 1978-1984.
|
| 8 |
Vickers AD, Winfree KB, Cuyun CG, et al. Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis[J]. BMC Cancer, 2019, 19(1): 353.
|
| 9 |
Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial[J]. JAMA Oncol, 2018, 4(11): 1569-1575.
|
| 10 |
Han B, Li K, Zhao Y, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase Ⅱ trial (ALTER0302)[J]. Br J Cancer, 2018, 118(5): 654-661.
|
| 11 |
石远凯，孙 燕，丁翠敏，等. 中国埃克替尼治疗非小细胞肺癌专家共识(2016年版)[J]. 中国肺癌杂志，2016, 19(7): 489-493.
|
| 12 |
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247.
|
| 13 |
Boyd MR, Paull KD. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen[J]. Drug Development Research, 2010, 34(2): 91-109.
|
| 14 |
伦文慧，李铁钢，毛 纯，等. 广州市城区居民肺癌死亡率和发病率趋势分析及预测[J]. 中国癌症防治杂志，2020, 12(1): 51-56.
|
| 15 |
Yoneda K, Imanishi N, Ichiki Y, et al. Treatment of non-small cell lung cancer with EGFR-mutations[J]. J UOEH, 2019, 41(2): 153-163.
|
| 16 |
张连民，岳东升，张真发，等. 非小细胞肺癌的外科及围手术期治疗研究进展[J]. 中国肿瘤临床，2021, 48(10): 488-494.
|
| 17 |
Haruna M, Hirata M, Iwahori K, et al. Docetaxel upregulates HMGB1 levels in non-small cell lung cancer[J]. Biol Pharm Bull, 2020, 43(3): 399-403.
|
| 18 |
Choi MG, Park S, Oh DK, et al. Effect of medical thoracoscopy-guided intrapleural docetaxel therapy to manage malignant pleural effusion in patients with non-small cell lung cancer: A pilot study[J]. Thorac Cancer, 2019, 10(10): 1885-1892.
|
| 19 |
Cascone T, Sepesi B, Lin H Y, et al. A phase Ⅰ/Ⅱ study of neoadjuvant cisplatin, docetaxel, and nintedanib for resectable non-small cell lung cancer[J]. Clin Cancer Res, 2020, 26(14): 3525-3536.
|
| 20 |
Chen R, Manochakian R, James L, et al. Emerging therapeutic agents for advanced non-small cell lung cancer[J]. J Hematol Oncol, 2020, 13(1): 58.
|
| 21 |
Xiao W, Ma W, Wei S, et al. High-affinity peptide ligand LXY30 for targeting alpha3beta1 integrin in non-small cell lung cancer[J]. J Hematol Oncol, 2019, 12(1): 56.
|
| 22 |
Serzan MT, Farid S, Liu SV. Drugs in development for small cell lung cancer[J]. J Thorac Dis, 2020, 12(10): 6298-6307.
|
| 23 |
Song Y, Miao L, Wang Z, et al. Combination of apatinib and docetaxel in treating advanced non-squamous non-small cell lung cancer patients with wild-type EGFR: a multi-center, phase Ⅱ trial[J]. J Thorac Dis, 2020, 12(5): 2450-2458.
|
| 24 |
刘细帮，朱林芝，焦德敏，等. 安罗替尼联合氯喹促进人非小细胞肺癌细胞系H1299凋亡[J]. 基础医学与临床，2021, 41(7): 1018-1023.
|
| 25 |
康 燕，高 景，宋蒙蒙，等. 安罗替尼联合顺铂对非小细胞肺癌患者NSE、TGF-β1、MMP-2的影响[J]. 重庆医学，2021, 50(1): 105-112,117.
|
| 26 |
Gao Y, Wang J, Zhou Y, et al. Evaluation of serum CEA, CA19-9, CA72-4, CA125 and ferritin as diagnostic markers and factors of clinical parameters for colorectal cancer[J]. Sci Rep, 2018, 8(1): 2732.
|
| 27 |
Feng F, Tian Y, Xu G, et al. Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer[J]. BMC Cancer, 2017, 17(1): 737.
|
| 28 |
刘喜婷，马 琴，李成彪，等. 多西紫杉醇与伊立替康分别联合顺铂治疗复发、耐药型小细胞肺癌疗效及安全性比较[J]. 山东医药，2021, 61(17): 62-64.
|
| 29 |
许 伦，李 英，尤 玮. GC化疗方案联合安罗替尼胶囊对晚期非小细胞肺癌患者生存状况的影响及其机制研究[J]. 实用心脑肺血管病杂志，2021, 29(1): 51-56.
|
| 30 |
吕艺华，赵子龙，黄革红，等. 安罗替尼联合伊立替康二线治疗小细胞肺癌的临床疗效及安全性[J]. 天津医药，2021, 49(4): 436-440.
|